Clinical trials: Chemotherapy
Anemia, Cancer
Use of Intravenous Ferric Carboxymaltose in Treatment of Anemia in Cancer Patients Undergoing Chemotherapy
This study is a nonrandomized, single arm, open-label study stratified by iron-deficiency status.
- Trial name
- NCT04246021
- Testing
- Ferric carboxymaltose (FCM)
- Volunteers
- 84 people
- Sponsor
- King Hussein Cancer Center
Adenocarcinoma of the Lung
A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
The primary objective of this study is to compare the effect of farletuzumab versus placebo in combination with either a platinum agent (carboplatin) with paclitaxel or a platinum agent (carboplatin or cisplatin) with pemetrexed…
- Trial name
- NCT01218516
- Testing
- Farletuzumab, Carboplatin, Paclitaxel
- Where
- 93 sites in United States, Australia and 6 more
- Volunteers
- 130 people
- Sponsor
- Morphotek
Multiple Myeloma, Hodgkin Disease
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
The purpose of this study is to find out whether acupuncture treatments can reduce the need for opioid medication when managing pain caused by chemotherapy.
- Conditions
- Multiple Myeloma, Hodgkin Disease, Non-Hodgkin Lymphoma
- Trial name
- NCT04459416
- Testing
- Acupuncture, opioid, Assessments
- Where
- 2 sites in United States
- Volunteers
- 299 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adjuvant, Chemotherapy
Drug Delivery and Toxicities of Adjuvant Chemotherapy in Resected NCSLC
There are limited numbers of retrospective studies showing the effectiveness of adjuvant chemotherapy over observation in resected lung cancers.
- Conditions
- Adjuvant, Chemotherapy, Lung, Cancers
- Trial name
- NCT00484016
- Volunteers
- 45 people
- Sponsor
- Washington University School of Medicine
Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer
Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC
This is a Phase II clinical trial evaluating the efficacy and safety of a new treatment approach for patients with locally advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes on the opposite side of the…
- Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer
- Trial name
- SACTION 2501 (NCT07309952)
- Testing
- Sintilimab, Paclitaxel, Carboplatin (AUC 5)
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Yang Hong
Fatigue, Cognitive Impairment
Cognitive Function After Stem Cell Transplantation
The trial will evaluate the effects of an exercise program on the physical and cognitive performance of patients with hematological neoplastic diseases after high dose chemotherapy with stem cell support.
- Conditions
- Fatigue, Cognitive Impairment, Stem Cell Transplantation
- Trial name
- NCT00884338
- Testing
- Endurance exercise, Counseling
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Charite University, Berlin, Germany
Esophageal Squamous Cell Carcinoma
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Surgical resection is currently the major treatment for esophageal carcinoma while disease progression still occurred in most cases within 3 years.
- Trial name
- NCT04390958
- Testing
- nab-paclitaxel, Cisplatin, Capecitabine
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Chinese Academy of Medical Sciences
Leukemia-Lymphoma, Adult T-Cell
EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma
The rationale of the current study is to explore the use of combination chemotherapy together with antiretroviral agents in order to determine the efficacy and toxicity of this approach, while also examining markers of virus…
- Trial name
- ATLL (NCT01000285)
- Testing
- Bortezomib, Etoposide, Vincristine
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Esophageal Cancer, Chemotherapy Effect
Neoadjuvant Treatment Modalities in Esophageal Cancer
Esophageal cancer is the most prevalent cancer globally with poor survival outcome. The prognosis with surgery alone is poor, accounting for 30-40% of overall survival at 5 year.
- Conditions
- Esophageal Cancer, Chemotherapy Effect, Chemoradiation, Surgery
- Trial name
- NCT04821843
- Testing
- Platinum based chemotherapy, Paclitaxel based chemotherapy, Radiotherpay
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer, Neutropenia
Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia
The overall purpose of this study is to assess the dose response, efficacy, and safety of three different dose levels of AVI 014 (granulocyte colony-stimulating factor [G-CSF]) in breast cancer patients at high (>20%) risk for…
- Trial name
- NCT00497809
- Testing
- AVI-014 versus Filgrastim
- Where
- 31 sites in United States, India
- Volunteers
- 189 people
- Sponsor
- AviGenics
Cannabis Use Disorder
Cannabidiol: a Novel Intervention for Cannabis Use Problems?
The purpose of this trial is to investigate a novel treatment for cannabis dependence: cannabidiol. Between 96 and 168 young people who want to quit cannabis and meet criteria for moderate cannabis use disorder (DSM-5) will be…
- Trial name
- NCT02044809
- Testing
- Cannabidiol
- Where
- United Kingdom
- Volunteers
- 82 people
- Sponsor
- University College, London
Epithelial Ovarian Cancer
A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.
The OReO study will be a Phase IIIb, randomised, double-blind, placebo-controlled, multicentre study to assess the efficacy and tolerability of Olaparib retreatment, versus matching placebo, in non-mucinous epithelial ovarian…
- Trial name
- OReO (NCT03106987)
- Testing
- Active Comparator: Olaparib tablets
- Where
- 82 sites in Belgium, Canada and 9 more
- Volunteers
- 220 people
- Sponsor
- AstraZeneca
Thrombocytopenia
Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients
In this single-center, randomized, open-label, crossover, prospective clinical trial, a total of 120 AML patients who achieved remission will be randomized into two groups, of 60 cases in each group.
- Trial name
- NCT02267993
- Testing
- recombinant human thrombopoietin
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
- Trial name
- NCT06105021
- Testing
- AFNT-211
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Affini-T Therapeutics, Inc.
Diffuse Large B Cell Lymphoma
A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma
A phase II trial of ifosfamide, etoposide, cytarabine, and methotrexate (IVAM) chemotherapy for refractory or relapsed diffuse large B cell lymphoma
- Trial name
- IVAM (NCT03383406)
- Testing
- Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy
- Volunteers
- 30 people
- Sponsor
- Asan Medical Center
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens
The purpose of this study is to determine whether deferasirox is effective in the treatment of acute lymphatic leukemia (ALL) and acute Myeloid leukemia (AML).
- Trial name
- NCT02413021
- Testing
- Cytarabine, Deferasirox
- Volunteers
- 40 people
- Sponsor
- Isfahan University of Medical Sciences
Overactive Bladder
Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy
This study evaluated the outcomes of women with detrusor overactivity treated with combined pharmacotherapy to identify risk factors for treatment failure.
- Trial name
- NCT07337252
- Testing
- Combined pharmacotherapy
- Where
- Taiwan
- Volunteers
- 61 people
- Sponsor
- Mackay Memorial Hospital
HIV Infections
A Study of Dideoxycytidine Plus Zidovudine (AZT) in HIV-Infected Children Who Have Taken AZT
PRIMARY: To determine safety, tolerance, and pharmacokinetics of zidovudine (AZT) and zalcitabine (dideoxycytidine; ddC) when given in combination in clinically stable AZT-treated children.
- Trial name
- NCT00001032
- Testing
- Zidovudine, Zalcitabine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 180 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Quality of Life
HRQoL in Advanced Soft Tissue Sarcoma Patients Treated With Chemotherapy.
The benefits of cancer treatments, such as chemotherapy, are traditionally measured by outcomes such as progression free survival and overall survival.
- Trial name
- NCT03621332
- Testing
- Questionnaire
- Where
- United Kingdom
- Volunteers
- 132 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Gastric Cancer, Chemotherapy Effect
Predicting Gastric Cancer Response to Chemo With Multimodal AI Model
This study aims to develop a multimodal model combining radiomic and pathomic features to predict pathological complete response (pCR) in advanced gastric cancer patients undergoing neoadjuvant chemotherapy (NAC).
- Trial name
- NCT06451393
- Testing
- Neoadjuvant chemotherapy with radical tumor resection surgery
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University